Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012)
PHASE3CompletedINTERVENTIONAL
Enrollment
943
Participants
Timeline
Start Date
October 15, 2004
Primary Completion Date
January 15, 2006
Study Completion Date
January 15, 2006
Conditions
MenopauseVasomotor Symptoms
Interventions
DRUG
esmirtazapine
DRUG
Placebo
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT00560833 - Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012) | Biotech Hunter | Biotech Hunter